This Morning from CBS News, Nov. 25, 2015
Russian response
President Putin was visibly angry after Turkish aircraft shot down a Russian fighter jet over Syria, and his most tangible response has come in the form of advanced surface-to-air missiles, and a threat to use them. With NATO and Russia seemingly in stark opposition in the Syria war, is there still any hope for cooperation?
European nerves
The hunt for Europe's most-wanted man, a key suspect still at large after the deadly attacks on Paris, is still going, but in the Belgian capital of Brussels -- from which a handful of the ISIS-linked militants came -- people are making a furtive attempt to get back to life as normal.
Kill or capture
The U.S.-led war in Afghanistan yielded hundreds of foreign terror suspects to for interrogation, but now, as President Obama promises to intensify the U.S. campaign against ISIS, it seems likely he'll rely more on lethal force. So why the change in tactic, and what are the implications for the long-term strategy?
NYPD on horseback
New York City police are ramping-up security for the millions expected to arrive for Thanksgiving, and the plans include the deployment of more police on horses. Officers say the specialized unit is a key part of the city's counter-terrorism strategy. We get a closer look at the animals helping keep New York safe and why they're so valuable.
Shrinking seats
The AAA predicts the number of people flying for Thanksgiving will climb to 3.6 million this year. But that's not the only reason passengers may feel a bit cramped. Over the last few years, airlines have reduced capacity. We look at how the largely unregulated battle for space in the sky is putting the squeeze on American fliers.
Card skimmers
Thieves may be trying to rob you blind -- at the gas pump. Scams using "skimming" technology to steal credit card information while people refuel their vehicles are on the rise. Here's what you need to know heading into the busy travel weekend.
Pharma windfall
Pfizer says the enormous tax savings it will get by acquiring Irish drugmaker Allergan for $160 billion will allow the merged company to invest in the U.S. and create jobs. But will it really? The recent history of Pfizer and other big U.S. companies suggests that may not be the case.
More top news:
U.S.
Chicago police shooting video sparks protests
Syrian refugees thankful in Kentucky
St. Louis Rams player reportedly shot in head
Newborn baby found in manger of N.Y. nativity scene
World
NATO urges calm after Turkey shoots down Russian jet
2 judges among victims in Egypt hotel attack
Doctors recount treating Paris attacks victims
Politics
Trump claims he predicted terrorism
Clinton meets gun violence survivors and families
Report: Plaque at Trump golf course historically inaccurate
Martin O'Malley unveils health care plan
Business
10 terrific holiday gifts for the home
The best Black Friday car deals
Science and Tech
Fighting terrorism? There's an app for that